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What is known? It has been recognized for about a decade
that short-acting formulations of dihydropyridine calcium an-
tagonists may be deleterious in acute ischemic syndromes. This
has been particularly clear with the immediate-release formu-
lation of nifedipine, for which multiple randomized clinical
trials have indicated trends for, or significant adverse effects
on, ischemia-related outcomes. The Trial of Early Nifedipine
in Acute Myocardial Infarction (TRENT) (1) included 4,091
patients treated within 48 h of onset of suspected myocardial
infarction (MI) and showed a trend toward more deaths (;7%
excess) at 28 days in patients assigned nifedipine. This trend was
consistent in subgroup analysis. For example, in the 1,180 patients
in whom treatment was initiated but not continued, mostly
because MI was not confirmed, the mortality rate was 9.7% in
those given nifedipine versus 9.1% in those given placebo. Pre-
sumably, these were mostly patients with unstable angina. Un-
favorable trends were also noted in those already receiving
beta-adrenergic blocking agents as well as those not receiving
beta-blockers at randomization. Then, the Holland Ischaemia
Nifedipine Trial (HINT) (2) of 668 patients with unstable angina
was terminated early because of excess MI in nifedipine-assigned
patients. At 48 h, 15% of placebo-assigned patients and 28% of
nifedipine-assigned patients had developed MI. Even in the
subgroup with ST segment elevation (presumably patients who
had coronary spasm) there was no evidence for benefit.
After these trials, where rapid-release nifedipine had been
given to patients presenting with an acute ischemic syndrome,
several trials were done in patients after confirmed MI. The
Secondary Prevention Reinfarction Israeli Nifedipine Trial
(SPRINT) (3) initiated treatment 7 to 21 days after MI,
whereas SPRINT II initiated treatment up to 2 days after MI
and used a higher nifedipine dose than SPRINT (60 vs. 30 mg)
(4). Again, both trials showed excess death and reinfarction in
nifedipine-assigned patients. These poor outcomes with
immediate-release short-acting nifedipine in acute ischemic
syndromes were rehighlighted in a recent meta-analysis of all
secondary prevention trials (5). These findings were not unex-
pected because others had established that patients with acute
MI given potent vasodilators intravenously do not do well (6).
What about nondihydropyridines? The situation appears
to be different with the nondihydropyridine antagonists regard-
less of immediate- or slow-release dosing forms. Data from the
first and second Danish Study Group on Verapamil in Myo-
cardial Infarction (DAVIT-I and II) studies (7,8), the Calcium
Antagonist Reinfarction Italian Studies (CRIS) of verapamil in
post-MI patients and four smaller trials (9–13) that totaled
over 4,000 patients overall suggested no harm and even some
evidence for benefit. The benefit derived from reducing either
reinfarction alone or, more appropriately, the aggregate out-
come of death or reinfarction. Although, most of these trials
used an oral immediate-release verapamil formulation,
DAVIT-I initiated treatment intravenously, and CRIS used a
slow-release preparation. More recent reports using verapamil
in a slow-release formulation with an angiotensin-converting
enzyme (ACE) inhibitor suggest improved left ventricular
function (11,14). One recent randomized pilot trial suggested
that verapamil added to an ACE inhibitor reduced cardiovas-
cular adverse outcomes in high risk post-MI patients with
systolic dysfunction compared with the ACE inhibitor alone
(11). Less pronounced but similar directional trends have been
observed in two studies comprising a total of ;3,000 patients
randomized to short-acting diltiazem (15,16).
What about newer agents? These findings with different
formulations and different types of calcium antagonists are not
entirely unexpected because the heterogeneity of the class of
calcium antagonists is well known. It perhaps needs to be
reemphasized that there are significant pharmacologic differ-
ences between slow-release, long-acting formulations and
rapid-release, short-acting formulations, even among those of
the same chemical entity, that include different hemodynamic
and neurohumoral effects (17,18). In addition, there is emerg-
ing evidence to suggest that some newer long-acting dihydro-
pyridine formulations may be beneficial in post-MI patients.
The recently reported Doppler Flow and Echocardiography in
Functional Cardiac Insufficiency: Assessment of Nisoldipine
Therapy (DEFIANT-II) study (19) assessed the effects of
slow-release, long-acting nisoldipine (coat-core) versus pla-
cebo on exercise, exercise-induced ischemia, left ventricular
function and clinical outcome in 542 patients with reduced
ejection fraction (median 38%) 7 to 10 days after MI. In these
high risk patients, approximately half of whom had an anterior
MI, long-acting nisoldipine was associated with improved
diastolic left ventricular function and strong trends toward
reduced cardiovascular events. The absence of harmful effects
in patients with coronary artery disease with impaired left
ventricular function (most likely due to remote MI) has also
been observed with the slow onset, long-acting dihydropyridine
amlodipine in the Prospective Randomized Amlodipine Survival
Evaluation (PRAISE) study (20). In that study, patients were
receiving ACE inhibitors, and amlodipine treatment was associ-
ated with an overall trend toward reduced cardiovascular events.
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What about case-control studies in post-MI patients? This
issue of the Journal contains a report by Leitch et al. (21) on
community-based follow-up of post-MI patients treated with
calcium antagonists, beta-blockers, both or neither. Neither
drug release/duration formulation nor dose were recorded;
however, very few patients received newer long-acting calcium
antagonist formulations. The investigators found that, com-
pared with those receiving a beta-blocker, calcium antagonist
recipients had higher rates of MI or cardiac death, cardiac
death and all-cause mortality (22). Calcium antagonist recipi-
ents were not at increased risk for these outcomes compared
with patients receiving neither beta-blockers nor calcium an-
tagonists, and compared with this latter group, there was no
increased risk of MI or cardiac death among patients who
received verapamil, diltiazem or nifedipine. The authors con-
clude that the findings support the benefit of beta-blocker
therapy after MI (22,23) and the absence of effect, rather than
a deleterious effect, of calcium antagonists on reinfarction and
mortality. However, the study is open to some of the same
methodologic objections leveled at previous retrospective anal-
yses of calcium antagonists in this setting: 1) The nonrandom
assignment of treatment allows for potential selection bias that
cannot be excluded as an explanation for the difference risk in
the calcium antagonist patients; 2) the retrospective design
omitted recording of drug formulation and dose, preventing
evaluation of differences in effect between short-acting and
long-acting agents; 3) the data captured had limited ability to
assess the severity and control of hypertension and associated
disorders, such as dyslipidemia, diabetes and other conditions,
including treatment adherence/compliance, which are all likely
to influence ischemia-related outcomes.
Questions raised by recent case-control studies about cal-
cium antagonist use (5,24) have emphasized our lack of
knowledge and, perhaps more important, the inherent weak-
nesses of case-control methodologies when applied to ischemic
heart disease with or without hypertension. Questions regard-
ing the risks and benefits of currently used and new slow-
release, longer-acting calcium antagonist formulations will be
answered only by large prospective, randomized, controlled
trials, and a number of these trials are planned or ongoing.
Finally, it may be important to note that the administrative-
type data, currently used to mold national health care strate-
gies, are also gathered by nonrandomized, case-control meth-
odology and as such are likely to be limited in the area of
ischemic heart disease. Perhaps we should use this opportunity
to demand more controlled trial data for these important
health policy-setting decisions before it is too late.
References
1. Wilcox RJ, Hampton JP, Banks DC, et al. Trial of early nifedipine in acute
myocardial infarction: the TRENT study. BMJ 1986;293:1214–8.
2. Holland Interuniversity Nifedipine (Metoprolol) Trial (HINT) Research
Group. Early treatment of unstable angina in the coronary care unit: a
randomized, double blind, placebo controlled comparison of recurrent
ischemia in patients treated with nifedipine or metoprolol or both. Br
Heart J 1986;56:400–13.
3. Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli
Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in
patients with acute myocardial infarction. Eur Heart J 1988;9:354–64.
4. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of
nifedipine in suspected acute myocardial infarction. Arch Intern Med
1993;153:345–53.
5. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortal-
ity in patients with coronary heart disease. Circulation 1995;92:1326–31.
6. Cohn JN, Franciosa JA, Francis GS et al. Effect of short-term infusion of
sodium nitroprusside on mortality rate in acute myocardial infarction
complicated by left ventricular failure: results of a Veterans Administration
cooperative study. N Engl J Med 1982;306:1129–35.
7. Danish Study Group on Verapamil in Myocardial Infarction (DAVIT-I).
Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516–28.
8. Danish Study Group on Verapamil in Myocardial Infarction. Effect of
verapamil on mortality and major events after acute myocardial infarction:
the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol
1990;66:779–85.
9. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in
patients after acute myocardial infarction: results of the Calcium Antagonist
Reinfarction Italian Study (CRIS). Am J Cardiol 1996;77:421–2.
10. Hansen JF, Sigurd B, Mellemgaard K, Lyngbye J. Verapmail in acute
myocardial infarction. Dan Med Bull 1980;27:105–9.
11. Hansen JF, Hagerup L, Sigurd B, et al., for the Danish Verapamil Infarction
Trial (DAVIT) Study Group. Cardiac event rates after acute myocardial
infarction in patients treated with verapamil and trandolapril versus tran-
dolapril alone. Am J Cardiol 1997;79:738–41.
12. Crea F, Deanfield J, Crean P, Sharon M, Davies G, Maseri A. Effects of
verapamil in preventing early post-infarction angina and reinfarction. Am J
Cardiol 1984;55:900–4.
13. Bussman WD, Ser W, Gruengrass M. Reduction of creatine kinase and
creatine kinase-MB indexes of infarct size by intravenous verapamil. Am J
Cardiol 1984;54:1224–30.
14. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM. Vera-
pamil and angiotensin-converting enzyme inhibitors in patients with coro-
nary artery disease and reduced left ventricular ejection fraction. Am J
Cardiol 1996;77:16D–21D.
15. Gibson RS, William F, Boden WF, et al. Diltiazem and reinfarction in patients
with non-Q-wave myocardial infarction. N Engl J Med 1986;315:423–9.
16. Multicenter Diltiazem Postinfarction Trial Research Group (MDPIT). The
effect of diltiazem on mortality and reinfarction after myocardial infarction.
N Engl J Med 1988;319:385–92.
17. Epstein M. Calcium antagonists should continue to be used for first-line
treatment of hypertension. Arch Intern Med 1995;155:2150–6.
18. Pepine CJ. The role of calcium antagonists in ischaemic heart disease. Eur
Heart J 1995;16 Suppl H:19–24.
19. The DEFIANT-II Research Group. Doppler flow and echocardiography in
functional cardiac insufficiency: assessment of nisoldipine therapy. Results of
the DEFIANT-II study. Eur Heart J 1997;18:31–40.
20. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity
and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107–14.
21. Leitch JW, McElduff P, Dobson A, Heller R. Outcome with calcium
antagonists after myocardial infarction: a community-based study. J Am Coll
Cardiol 1998;31:111–7.
22. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial
infarction: an overview of the randomised trials. Prog Cardiovasc Dis
1985;27:335–71.
23. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of
underuse of beta-blockers in elderly survivors of acute myocardial infarction.
JAMA 1997;277:115–21.
24. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction
associated with antihypertensive drug therapies. JAMA 1995;274:620–5.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CRIS 5 Calcium Antagonist Reinfarction Italian Studies
DAVIT 5 Danish Study Group on Verapamil in Myocardial Infarction
(trial)
MI 5 myocardial infarction
SPRINT 5 Secondary Prevention Reinfarction Israeli Nifedipine Trial
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